Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

(2020) Hani M. Babiker et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

(2019) Andrew H. Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

(2019) Michael R Savona et al.   Lancet Haematology

Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies

(2018) Michael R. Savona et al.   AMERICAN JOURNAL OF HEMATOLOGY

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

(2018) Marcos de Lima et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia

(2018) Guillermo Garcia-Manero et al.   LEUKEMIA RESEARCH

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study

(2017) Robert Molokie et al.   PLOS MEDICINE

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

(2015) Eric Laille et al.   PLoS One

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

(2013) R. Z. Mahfouz et al.   CLINICAL CANCER RESEARCH

Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients

(2013) Makoto Ishitobi et al.   Patient Preference and Adherence

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

(2011) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

(2009) Roger M. Lyons et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY